Advertisement
U.S. markets open in 1 hour 21 minutes
  • S&P Futures

    5,305.25
    -3.00 (-0.06%)
     
  • Dow Futures

    40,143.00
    -1.00 (-0.00%)
     
  • Nasdaq Futures

    18,488.25
    -15.50 (-0.08%)
     
  • Russell 2000 Futures

    2,141.60
    +3.20 (+0.15%)
     
  • Crude Oil

    82.39
    +1.04 (+1.28%)
     
  • Gold

    2,231.70
    +19.00 (+0.86%)
     
  • Silver

    24.67
    -0.08 (-0.33%)
     
  • EUR/USD

    1.0791
    -0.0039 (-0.36%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    13.03
    +0.25 (+1.96%)
     
  • GBP/USD

    1.2618
    -0.0020 (-0.16%)
     
  • USD/JPY

    151.3370
    +0.0910 (+0.06%)
     
  • Bitcoin USD

    70,576.44
    +298.53 (+0.42%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.37
    +20.39 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Cara Therapeutics Presents Results of Oral Difelikefalin In Painful Itching Disorder

  • Cara Therapeutics Inc (NASDAQ: CARAannounced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for moderate-to-severe pruritus in notalgia paresthetica (NP).

  • Notalgia paresthetica (NP) is a nerve disorder that causes intense and sometimes painful itching in the back impacting quality of life.

  • The data will be presented at the European Academy of Dermatology and Venereology (EADV) Congress.

  • The presentation includes data from 125 patients with NP and moderate-to-severe pruritus who were randomized to receive oral difelikefalin 2 mg twice daily or a placebo over an 8-week treatment period.

  • The primary efficacy endpoint of change from baseline in the weekly mean of the itch score was achieved (-4.0 difelikefalin vs. -2.4 placebo). A statistically significant reduction in itch intensity was observed with oral difelikefalin at Day 1 compared to placebo, and the effect was maintained through Week 8.

  • A significantly greater proportion of patients achieved a ≥4-point improvement in the itch score at Week 8 with oral difelikefalin vs. placebo (41% difelikefalin vs. 18% placebo, p=0.007).

  • A higher proportion of patients receiving oral difelikefalin vs. placebo achieved a complete response (22% difelikefalin vs. 5% placebo)

  • Oral difelikefalin was generally well tolerated, with all adverse events in difelikefalin-treated patients reported as mild or moderate in severity.

  • Price Action: CARA shares are down 0.27% at $10.93 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement